© 2000 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Effect of Simvastatin Therapy on Paraoxonase Activity and Related Lipoproteins in Familial Hypercholesterolemic Patients
From Unitat de Lípids i Epidemiologia Cardiovascular, Institut Municipal d’Investigació Mèdica, IMIM, Barcelona, and ABS Llefiá (F.G.-F.), Badalona, Spain.
Abstract—Human paraoxonase (PON1) is a calcium-dependent esterase closely associated with high density lipoprotein (HDL)-containing apolipoprotein AI (apoAI), which has been shown to confer antioxidant properties to HDL. PON1 has been recently implicated in the pathogenesis of atherosclerosis. Low PON1 activities have been found in familial hypercholesterolemia (FH) and diabetes mellitus. We have undertaken a study of the effect of the lipid-lowering drug simvastatin on serum PON1 activity (in relation to paraoxon and arylesterase activity), on apoAI-containing and apolipoprotein B (apoB)-containing lipoproteins, and on lipid peroxide concentrations in 64 (39 women and 25 men) unrelated FH patients. We have also analyzed the influence of the PON1-192 and PON1-55 genetic polymorphisms on the response of PON1 activity to simvastatin therapy. A venous blood sample for a baseline analysis and another after 4 months of simvastatin therapy at a dosage of 20 mg per day were taken. The major effect of simvastatin on lipid traits was to decrease serum cholesterol, low density lipoprotein (LDL) cholesterol, and lipid peroxide concentrations by 19.9%, 26.3%, and 37.3%, respectively. There was also a significant decrease in serum apoB, LDL apoB, and triglyceride concentrations (20.5%, 21.1%, and 15.6%, respectively). Conversely, simvastatin had no significant influence on very low density lipoprotein–lipid content, HDL cholesterol, apoAI concentrations, and lipoprotein AI and AI:AII particles. Remarkably, serum PON1 activity toward paraoxon significantly increased during treatment with simvastatin (168.7±100.3 U/L before therapy versus 189.5±116.5 U/L after therapy, P=0.005). Arylesterase activity displayed only a nonsignificant trend to increase after therapy. Whereas PON1 activity levels were significantly lower in FH patients before simvastatin therapy compared with those of 124 normolipidemic subjects (168.7±100.3 versus 207.6±125.2 U/L, respectively; P<0.05), this difference disappeared after simvastatin therapy. After simvastatin therapy, a significantly negative correlation between PON1 activity and lipid peroxide concentration was observed (r=-0.35, P=0.028). The latter also strongly correlated with LDL cholesterol concentration (r=0.64, P<0.001). Serum PON1 activity levels were significantly lower in the low-activity PON1-192 QQ and PON1-55 M carriers than in R carriers and in LL carriers, respectively. No significant differences were found in the therapeutic response of PON1 activity between genotype groups (8.5% and 11.1% increase for QQ homozygous and R-carrier FH patients, respectively, and 12.7% and 9.5% increase for LL homozygotes and M carriers, respectively). We conclude that simvastatin may have important antioxidant properties through increasing serum PON1 activity, perhaps as a consequence of reducing oxidative stress, by a mechanism independent of apoAI-containing lipoprotein concentration and without the influence of PON1-192 and PON1-55 genetic polymorphisms. Further studies are clearly warranted to clarify the precise mechanism by which simvastatin therapy is associated with increased PON1 activity.
Key Words: familial hypercholesterolemia • paraoxonase • PON1 genotypes • simvastatin
This article has been cited by other articles:
 |
|
 |
|
  J. R. Batuca, P. R. J. Ames, M. Amaral, C. Favas, D. A. Isenberg, and J. Delgado Alves Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus Rheumatology, January 1, 2009; 48(1): 26 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Cangemi, L. Loffredo, R. Carnevale, L. Perri, M. P. Patrizi, V. Sanguigni, P. Pignatelli, and F. Violi Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E Eur. Heart J., January 1, 2008; 29(1): 54 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nus, F. Frances, J. Librelotto, A. Canales, D. Corella, J. M. Sanchez-Montero, and F. J. Sanchez-Muniz Arylesterase Activity and Antioxidant Status Depend on PON1-Q192R and PON1-L55M Polymorphisms in Subjects with Increased Risk of Cardiovascular Disease Consuming Walnut-Enriched Meat J. Nutr., July 1, 2007; 137(7): 1783 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Canales, J. Benedi, M. Nus, J. Librelotto, J. M Sanchez-Montero, and F. J. Sanchez-Muniz Effect of Walnut-Enriched Restructured Meat in the Antioxidant Status of Overweight/Obese Senior Subjects with at Least One Extra CHD-Risk Factor J. Am. Coll. Nutr., June 1, 2007; 26(3): 225 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Charlton-Menys, Y. Liu, and P. N. Durrington Semiautomated Method for Determination of Serum Paraoxonase Activity Using Paraoxon as Substrate Clin. Chem., March 1, 2006; 52(3): 453 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nguyen and D.-E. Sok Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids J. Lipid Res., December 1, 2004; 45(12): 2211 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rosenblat, T. Hayek, K. Hussein, and M. Aviram Decreased Macrophage Paraoxonase 2 Expression in Patients With Hypercholesterolemia Is the Result of Their Increased Cellular Cholesterol Content: Effect of Atorvastatin Therapy Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 175 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Senti, M. Tomas, M. Fito, T. Weinbrenner, M.-I. Covas, J. Sala, R. Masia, and J. Marrugat Antioxidant Paraoxonase 1 Activity in the Metabolic Syndrome J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5422 - 5426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Deakin, I. Leviev, S. Guernier, and R. W. James Simvastatin Modulates Expression of the PON1 Gene and Increases Serum Paraoxonase: A Role for Sterol Regulatory Element-Binding Protein-2 Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 2083 - 2089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ferre, J. Camps, J. Fernandez-Ballart, V. Arija, M. M. Murphy, S. Ceruelo, E. Biarnes, E. Vilella, M. Tous, and J. Joven Regulation of Serum Paraoxonase Activity by Genetic, Nutritional, and Lifestyle Factors in the General Population Clin. Chem., September 1, 2003; 49(9): 1491 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Jarvik, T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1465 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gouedard, N. Koum-Besson, R. Barouki, and Y. Morel Opposite Regulation of the Human Paraoxonase-1 Gene PON-1 by Fenofibrate and Statins Mol. Pharmacol., April 1, 2003; 63(4): 945 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Di Napoli, A.A. Taccardi, M. Oliver, and R. De Caterina Statins and stroke: evidence for cholesterol-independent effects Eur. Heart J., December 2, 2002; 23(24): 1908 - 1921. [PDF]
|
|
|
|
|
|
M. Rantala, M.-L. Silaste, A. Tuominen, J. Kaikkonen, J. T. Salonen, G. Alfthan, A. Aro, and Y. A. Kesaniemi Dietary Modifications and Gene Polymorphisms Alter Serum Paraoxonase Activity in Healthy Women J. Nutr., October 1, 2002; 132(10): 3012 - 3017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.N. Durrington, B. Mackness, and M.I. Mackness The Hunt for Nutritional and Pharmacological Modulators of Paraoxonase Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1248 - 1250. [Full Text] [PDF]
|
|
|
|
|
|
G. P. Jarvik, N. T. Tsai, L. A. McKinstry, R. Wani, V. H. Brophy, R. J. Richter, G. D. Schellenberg, P. J. Heagerty, T. S. Hatsukami, and C. E. Furlong Vitamin C and E Intake Is Associated With Increased Paraoxonase Activity Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1329 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Delbosc, J.-P. Cristol, B. Descomps, A. Mimran, and B. Jover Simvastatin Prevents Angiotensin II-Induced Cardiac Alteration and Oxidative Stress Hypertension, August 1, 2002; 40(2): 142 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Tsimihodimos, S.-A. P. Karabina, A. P. Tambaki, E. Bairaktari, J. A. Goudevenos, M. J. Chapman, M. Elisaf, and A. D. Tselepis Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 306 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Durrington, B. Mackness, and M. I. Mackness Paraoxonase and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., April 1, 2001; 21(4): 473 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Senti, M. Tomas, J. Marrugat, R. Elosua, and f. t. REGICOR Investigators Paraoxonase1-192 Polymorphism Modulates the Nonfatal Myocardial Infarction Risk Associated With Decreased HDLs Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 415 - 420. [Abstract] [Full Text] [PDF]
|
|